A growing literature has examined how mandatory access prescription drug monitoring programs (MA PDMPs), laws that require providers to consider a patient's prescription history before prescribing controlled substances, affect opioid‐related outcomes. However, evidence of their impact on non‐opioid‐related prescribing is mixed. This paper investigates the effect of MA PDMPs on prescribing patterns of stimulants and benzodiazepines. Using updated difference‐in‐differences methodology, we show that MA PDMPs led to decreases in stimulant prescribing but had no significant effects on benzodiazepine prescribing. Our findings highlight that MA PDMPs do have effects on non‐opioid drug prescribing, but these effects differ substantially across drug types.